CytoSorbents(US:CTSO)2024-03-14 16:00Financial Performance - Total revenue for the year ended December 31, 2023, was approximately $36,349,000, an increase of 5% from $34,689,000 in 2022[131]. - Revenue from CytoSorb product sales increased by 9% to approximately $31,015,000 in 2023, compared to $28,573,000 in 2022[131]. - Gross profit for 2023 was approximately $22,392,000, reflecting an 8% increase from $20,733,000 in 2022[135]. - Product gross margins improved to approximately 72% in 2023, up from 70% in 2022, primarily due to the resolution of production inefficiencies[133]. - Research and development expenses rose by 4% to approximately $15,729,000 in 2023, driven by pre-production and pre-commercialization activities[136]. - Legal, financial, and consulting expenses increased by 50% to approximately $4,272,000 in 2023, largely due to higher legal fees and consulting costs[137]. - Selling, general, and administrative expenses decreased by 2% to approximately $33,600,000 in 2023, attributed to lower sales and marketing costs[138]. - The gain on foreign currency transactions was approximately $1,949,000 in 2023, compared to a loss of approximately $2,449,000 in 2022, influenced by the Euro's exchange rate[139]. Product Development and Regulatory Approvals - The company’s flagship product, CytoSorb®, is approved in the EU for use in critical illnesses and has received multiple label expansions, including for the removal of ticagrelor and rivaroxaban during surgeries[115]. - The company completed the STAR-T trial for its DrugSorb-ATR Antithrombotic Removal System, which aims to prevent perioperative bleeding complications, and is pursuing regulatory approval from the FDA and Health Canada[115]. - The company received FDA Breakthrough Designation for the removal of Direct Oral Anticoagulants in cardiopulmonary bypass circuits, enhancing its product portfolio[120]. - CytoSorb has received multiple CE-Mark label expansions, including for the removal of bilirubin and myoglobin, and for the anti-platelet agent ticagrelor[159]. - The company has initiated two U.S. clinical trials for DrugSorb-ATR, with the first trial, STAR-T, focusing on preventing perioperative bleeding complications[159]. - The STAR-T clinical trial completed enrollment in July 2023, with 140 patients, and the final database lock occurred in December 2023[159]. - The Data Safety Monitoring Board (DSMB) found no safety concerns in the STAR-T trial, meeting the primary safety endpoint[171]. - The STAR-T trial did not meet the primary effectiveness endpoint in the overall patient population, but showed reduced bleeding complications in the isolated CABG surgery population[171]. Market Presence and Sales - The company has established direct sales or distribution of CytoSorb in over 75 countries worldwide, with CE Mark approval facilitating registration in EU countries typically within several months[234]. - CytoSorb has been utilized in over 228,000 human treatments globally, indicating strong market adoption and potential for future growth[117]. - The company has expanded its direct sales efforts into Belgium, Luxembourg, Poland, and the Netherlands, enhancing its market presence in Europe[217]. - The marketing agreement with Fresenius Medical Care establishes a global collaboration to promote CytoSorb alongside Fresenius' critical care products, with an initial term of three years[230]. - A preferred supplier agreement with Asklepios allows CytoSorb to be available without restrictions in approximately 170 healthcare facilities across 14 states in Germany[228]. Financial Management and Capital Structure - The company raised approximately $9,785,000 from a registered direct offering on December 13, 2023, selling 7,733,090 shares at a combined purchase price of $1.33[188]. - The company has raised approximately $229 million from investors as of December 31, 2023, to fund product development, clinical studies, and manufacturing capacity[248]. - On December 13, 2023, the company closed a registered direct offering, selling 7,733,090 shares of common stock and warrants for a total of approximately $10,285,000, with net proceeds of about $9,785,000[250]. - The company sold 2,656,464 shares under the Open Market Sale Agreement in 2023, generating net proceeds of approximately $4,532,000 at an average selling price of $1.76 per share[255]. - The company has made several amendments to its loan and security agreements, reflecting ongoing financial management and adjustments to its capital structure[293]. Corporate Governance and Compliance - The financial statements include consolidated balance sheets, statements of operations, and cash flows, which are essential for assessing the company's financial health[291]. - The company has incorporated information regarding executive compensation and director compensation from its proxy statement, indicating a structured approach to governance[288]. - The company has ongoing relationships and transactions with related parties, which are disclosed in the proxy statement, highlighting potential conflicts of interest[288]. - The company has outlined its principal accounting fees and services in the proxy statement, ensuring transparency in financial reporting[289]. - The company has a long-term incentive plan in place, which is referenced in its filings, indicating a commitment to aligning executive compensation with performance[293]. - The company is focused on maintaining director independence and governance matters, as detailed in its proxy statement, which is crucial for investor confidence[288]. - The company is preparing to disclose its stockholder information and equity compensation plans, which are important for understanding ownership structure and incentives[287]. Operational Facilities - The company operates leased facilities in Princeton, New Jersey, and Berlin, Germany, with a warehouse lease in Berlin requiring monthly payments of approximately $7,800[267]. - The company has a monthly base rent of approximately $117,000 for its new operating facility in Princeton, New Jersey, which commenced in April 2021 and will expire in March 2037[100]. - The company’s leases in Berlin, Germany, require combined base rent payments of approximately $12,100 per month, with a lease term ending on August 31, 2026[98]. - The new global headquarters and manufacturing facility in Princeton, New Jersey, is designed to support annual sales of up to $400 million and improve product gross margins[223]. Research and Development - The company’s technology aims to address limitations in hemodialysis by effectively removing larger toxins from the blood, enhancing patient outcomes[257]. - Since 2012, the company has been awarded approximately $41.4 million in grants and contracts from various U.S. government agencies to develop technologies for sepsis, trauma, and burn injury[256].